By Dennis Ford, Founder & CEO, LSN
Biotech and medtech industry executives are already drawing up their itineraries for January’s healthcare conference week in San Francisco. It’s on track to be a busy week for us all. Among the many events and receptions taking place, the Redefining Early Stage Investments Conference (RESI SF) stands alone in providing a targeted opportunity for early stage biotech and medtech companies to schedule up to 16 face-to-face investor meetings in one venue, with the potential for many more ad-hoc investor discussions throughout the day.
Partnering is RESI’s core, but at RESI SF also provides a full day of investor panels and workshops devoted to early stage life science investment topics. We’ll see the return of the RESI Asia-North America track, with content for entrepreneurs who are looking to the Asia Pacific region as a source of investment or future customers. RESI will also feature sessions focused on investors in each main life science technology vertical, and on key investor categories including Family Offices, Angels and Big Pharma, and a new session on Tech Giants in Healthcare.
With a full day of content and meetings, we’re on course for another sellout San Francisco RESI event. Don’t leave it too late to get your ticket.